Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years * Patient with Hurley HS II (moderate severity) or III (very severe) * Axillomammary (LC1) or gluteal (LC3) phenotype with at least 4 inflammatory lesions: inflammatory nodule, abscess or active fistula * Having presented at least one relapse to a well-conducted medical treatment as proposed by the 2019 French Dermatology Society evidence center recommendations (broad-spectrum antibiotic therapy for 15 to 21 days followed by prophylactic treatment with doxycycline or cotrimoxazole). A relapse is defined as the occurrence of a new attack within 3 months of the introduction of treatment. Exclusion Criteria: * Allergy or contraindication to amoxicillin-clavulanic acid * Patient having received biomedication in the 3 months prior to inclusion * Patient suffering from another inflammatory disease (IBD, inflammatory rheumatism, auto-inflammatory disease) * Concomitant Clostridioides Difficile infection * Immunocompromised patients * HIV infection and active HBV/HCV hepatitis * No health insurance * Pregnant or breast-feeding women * Patients already included in a biomedical research study other than an observational study (e.g. registry, cohort) * Patients under guardianship/curatorship/legal protection